Data as of Dec 06
| +0.01 / +0.17%|
XOMA discovers and develops innovative antibody-based therapeutics. It combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. The company focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. It is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Servier through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. The company's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators that could have a major effect on the treatment of diabetes. XOMA was founded in 1981 and is headquartered in Berkeley, CA.
|John W. Varian||Chief Executive Officer & Director|
|Fred Kurland||Chief Financial Officer, Secretary & VP|
|Patrick J. Scannon||Director, Chief Scientific Officer & EVP|
|Mark L. White||Vice President-Research|
|Charles C. Wells||VP-Human Resources & Information Technology|